We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-3.89%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.3B
AUM Growth
-$140M
Cap. Flow
+$106M
Cap. Flow %
4.61%
Top 10 Hldgs %
42.59%
Holding
80
New
11
Increased
12
Reduced
36
Closed
4

Top Buys

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$37.7M
2
DXCM icon
DexCom
DXCM
+$37.6M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$34.7M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$33.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$31.7M

Top Sells

Rank Stock Value
1
ONEM
1Life Healthcare
ONEM
+$38.9M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$38.2M
3
PLRX icon
Pliant Therapeutics
PLRX
+$27.1M
4
AKRO
Akero Therapeutics
AKRO
+$26.2M
5
REPL icon
Replimune Group
REPL
+$24.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.91%
2 Industrials 1.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
26
Bristol-Myers Squibb
BMY
$136B
$31.2M 1.35%
+449,442
New +$31.7M
RGNX icon
27
Regenxbio
RGNX
$638M
$31M 1.35%
1,640,725
-272,787
-14% -$6.04M
IMGN
28
DELISTED
Immunogen Inc
IMGN
$30.9M 1.34%
8,046,217
-486,600
-6% -$2.07M
ELV icon
29
Elevance Health
ELV
$85.5B
$30.5M 1.32%
66,398
+27,428
+70% +$13.1M
VTYX
30
DELISTED
Ventyx Biosciences
VTYX
$27.3M 1.19%
815,774
-79,200
-9% -$3.08M
TRDA icon
31
Entrada Therapeutics
TRDA
$273M
$26.6M 1.15%
1,831,608
-22,500
-1% -$300K
ADCT icon
32
ADC Therapeutics
ADCT
$146M
$26.5M 1.15%
13,565,249
+5,974,400
+79% +$22M
HUM icon
33
Humana
HUM
$46.3B
$25.3M 1.1%
+52,079
New +$25.7M
AUGX
34
DELISTED
Augmedix, Inc. Common Stock
AUGX
$25M 1.09%
14,380,327
– –
SRRK icon
35
Scholar Rock
SRRK
$7.04B
$25M 1.08%
3,124,226
+1,028,406
+49% +$10.4M
RPTX
36
DELISTED
Repare Therapeutics
RPTX
$24.9M 1.08%
2,533,050
-151,346
-6% -$1.74M
PRME icon
37
Prime Medicine
PRME
$655M
$24.5M 1.06%
1,992,843
-216,507
-10% -$3.53M
NRIX icon
38
Nurix Therapeutics
NRIX
$2.72B
$24.4M 1.06%
2,749,384
-251,400
-8% -$2.62M
STVN icon
39
Stevanato
STVN
$5.74B
$23.4M 1.01%
901,932
-40,593
-4% -$871K
CRL icon
40
Charles River Laboratories
CRL
$13.9B
$23.3M 1.01%
+115,328
New +$26.1M
IMVT icon
41
Immunovant
IMVT
$8.51B
$20.4M 0.89%
1,317,031
+228,900
+21% +$3.97M
GRTS
42
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$19.3M 0.84%
6,926,926
-4,534
-0.1% -$13K
CNC icon
43
Centene
CNC
$32B
$17.5M 0.76%
277,351
-3,909
-1% -$278K
STTK icon
44
Shattuck Labs
STTK
$707M
$16.5M 0.72%
5,619,914
– –
ATRA icon
45
Atara Biotherapeutics
ATRA
$92.3M
$16.3M 0.71%
224,482
-25,228
-10% -$2.45M
VERV
46
DELISTED
Verve Therapeutics
VERV
$16.2M 0.7%
1,120,679
-101,224
-8% -$1.98M
IQV icon
47
IQVIA
IQV
$43.1B
$14.3M 0.62%
+71,657
New +$15.3M
ABSI icon
48
Absci
ABSI
$1.49B
$14.1M 0.61%
8,031,094
– –
ETNB
49
DELISTED
89bio
ETNB
$13.7M 0.59%
+900,000
New +$11.7M
ANNX icon
50
Annexon
ANNX
$942M
$13.5M 0.59%
3,503,190
– –
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2023 Portfolio in Review

As of Q1 2023, Redmile Group held 80 positions worth $2.3B, down 5.7% from $2.44B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $106M of net new capital in Q1 2023, opening 11 new positions and adding to 12 existing holdings. Its largest new stake was CATALENT, INC.: 610,304 shares worth $40.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $38.2M trimmed.

  • Redmile Group's largest Q1 2023 buy was CATALENT, INC.: 610,304 shares worth $40.1M.
  • Redmile Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2023, an estimated $33.2M increase.
  • Redmile Group's biggest Q1 2023 reduction was Xenon Pharmaceuticals, cutting an estimated $38.2M.
  • Redmile Group fully exited 1Life Healthcare in Q1 2023, selling an estimated $38.9M.
  • Redmile Group's ten largest holdings make up 43% of its $2.3B portfolio in Q1 2023.
  • Redmile Group opened 11 new positions and closed 4 in Q1 2023.
  • Redmile Group's portfolio value fell 5.7% quarter-over-quarter to $2.3B.

Based on Redmile Group's 13F filing for Q1 2023, filed 15 May 2023.